Article Details

Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA

Retrieved on: 2021-08-02 10:41:15

Tags for this article:

Click the tags to see associated articles and topics

Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA. View article details on hiswai:

Excerpt

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up